Breaks Categories: News

TuesdayApr 28, 2020 10:15 am

CannabisNewsBreaks – Champignon Brands Inc. (CSE: SHRM) (OTCQB: SHRMF) (FWB: 496) Chosen as Headline Partner for PSYCH: The Psychedelics Symposium

Champignon Brands (CSE: SHRM) (OTCQB: SHRMF) (FWB: 496), a human optimization sciences company focused on applying novel and natural treatment protocols to address a broad range of disorders and deficiencies with an emphasis on psychedelic medicine, today announced that it has been chosen as the Headline Partner for Prohibition Partners LIVE’s PSYCH: The Psychedelics Symposium (“PSYCH”). The psychedelics virtual conference, scheduled to take place June 22 - 23, 2020, will highlight the most recent developments in the psychedelic industry, hear from world-renowned speakers and engage with a network of industry-leading professionals. “The impact of COVID-19 has put greater emphasis on…

Continue Reading

MondayApr 27, 2020 10:17 am

CannabisNewsBreaks – Supreme Cannabis Company, Inc. (TSX: FIRE) (OTCQX: SPRWF) (FRA: 53S1) Appoints Proven Leader in Canadian CPG Sector, Beena Goldenberg, as President and CEO

Supreme Cannabis Company (TSX: FIRE) (OTCQX: SPRWF) (FRA: 53S1) today announced that its board of directors (the “Board”) has named Beena Goldenberg, former CEO of Hain-Celestial Canada ("Hain Canada"), as the Company's president and chief executive officer, effective immediately. According to the update, Goldenberg succeeds Colin Moore who, as interim president and CEO since January 2020, took significant steps to reduce the Company's operating and overhead costs, expand its product offering across all market segments and accelerate its transition into a premium cannabis consumer packaged goods ("CPG") company. Moore will continue to serve as a director of the Company and…

Continue Reading

MondayApr 27, 2020 9:48 am

CannabisNewsBreaks – Plus Products Inc. (CSE: PLUS) (OTCQX: PLPRF) Releases Update on Timing of Annual Filings

Plus Products (CSE: PLUS) (OTCQX: PLPRF) on Friday announced that, as a result of the COVID-19 pandemic, it will be relying on the coordinated relief provided by the securities regulators, which consists of a 45-day extension for certain periodic filings, as announced by the Canadian Securities Administrators (“CSA“) on March 18, 2020. According to the update, Plus Products will rely on this relief with respect to the filing of its annual financial statements, management’s discussion and analysis, and related officer certificates for its financial year ended December 31, 2019. The Company will provide a further update concerning the exact timing…

Continue Reading

ThursdayApr 23, 2020 10:19 am

CannabisNewsBreaks – Champignon Brands Inc. (CSE: SHRM) (OTCQB: SHRMF) (FWB: 496) Commences Trading on the OTCQB Venture Market

Champignon Brands (CSE: SHRM) (OTCQB: SHRMF) (FWB: 496), a human optimization sciences company focused on applying novel and natural treatment protocols to address a broad range of disorders and deficiencies with an emphasis on psychedelic medicine, today announced that its common shares have graduated from the OTC Pink Open Market to the OTCQB Venture Market (the “OTCQB”), a U.S. trading platform operated by the OTC Markets Group. Effective immediately, Champignon Brands will commence trading on the OTCQB under the ticker symbol “SHRMF.” Champignon’s common shares will continue to trade under the ticker symbol “SHRM” on the Canadian Securities Exchange as…

Continue Reading

ThursdayApr 23, 2020 10:10 am

CannabisNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Announces Notice of Allowance for New Patent, Issuance of Stock Options Under Equity Incentive Plan

Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP), a global innovator in drug delivery platforms, today announced its receipt of a Notice of Allowance from the United States Patent and Trademark Office ("USPTO") for a new patent. According to the update, the new patent provides additional claims that protect the use of its DehydraTECH(TM) technology together with cannabinoids, nicotine, nonsteroidal anti-inflammatory drugs, or vitamins in mix and serve beverage formats. This patent, with application number 16/497,920 under the title "Food and Beverage Compositions Infused With Lipophilic Active Agents and Methods of Use Thereof," signifies another addition to Lexaria's first patent family, under…

Continue Reading

WednesdayApr 22, 2020 11:59 am

CannabisNewsBreaks – The Flowr Corporation (TSX.V: FLWR) (OTC: FLWPF) Announces Private Placement, Date for Release of Q4 Earnings

The Flowr Corporation (TSX.V: FLWR) (OTC: FLWPF) on Tuesday announced a non-brokered private placement for gross proceeds of C$20,000,000, with, at the company’s discretion, the ability to upsize the amount to an aggregate gross proceeds of C$25,000,000. According to the update, the company expects to use the proceeds of the Offering for general working capital purposes. “Despite the challenging capital markets environment, we are extremely fortunate to announce this financing and to have continued support from management and insiders who have been instrumental in Flowr’s founding, strategic direction and financing since inception,” Flowr’s CEO Vinay Tolia stated in the news…

Continue Reading

WednesdayApr 22, 2020 9:25 am

CannabisNewsBreaks – Champignon Brands Inc. (CSE: SHRM) (OTC: SHRMF) (FWB: 496) Research Partner Secures Steady Psilocybin Supply for Clinical Studies

Champignon Brands (CSE: SHRM) (OTC: SHRMF) (FWB: 496), a human optimization sciences company that is advancing its clinical pipeline through its ongoing TBI/PTSD-focused preclinical studies at the University of Miami’s Miller School of Medicine, today announced that its research partner and lead investigator, Dr. Michael Hoffer, has obtained a sustainable supply of psilocybin under a DEA schedule I license, which will be used for ongoing psilocybin-based therapeutics studies. Under a collaborative research agreement with the University of Miami's Miller School of Medicine, Champignon’s wholly owned subsidiary, Tassili Life Sciences Corp., is conducting preclinical studies and eventual human clinical trials, with…

Continue Reading

TuesdayApr 21, 2020 9:46 am

CannabisNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Files New Patent Application for DehydraTECH Technology in Delivery of Antiviral Drugs

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP), a global innovator in drug delivery platforms, today announced that it has filed an important new patent application in the United States describing the use of its DehydraTECH(TM) technology for the delivery of antiviral drugs. According to the update, the technology would potentially be used to improve treatment options for viral infectious diseases including COVID-19, MERS, SARS, influenza, herpes, hepatitis and AIDS. "Lexaria's proprietary drug delivery platform has already proven its effectiveness in the oral delivery of other lipophilic drugs such as nicotine, cannabinoids, and more, with multi-fold increases in both the rate…

Continue Reading

FridayApr 17, 2020 1:50 pm

CannabisNewsBreaks – Champignon Brands Inc. (CSE: SHRM) (OTC: SHRMF) (FWB: 496) Secures DTC Eligibility

Champignon Brands (CSE: SHRM) (OTC: SHRMF) (FWB: 496), a human optimization sciences company focused on applying novel and natural treatment protocols to address a broad range of disorders and deficiencies with an emphasis on psychedelic medicine, today announced that its common shares are now fully eligible for electronic clearing and settlement through the Depository Trust Company (“DTC”). Champignon’s common shares will continue to trade under the ticker symbol “SHRMF” on the OTC Markets. “We are actively engaged in pursuing new avenues of distribution both in North America and internationally, in order to enhance the ability of larger audiences to participate…

Continue Reading

ThursdayApr 16, 2020 10:15 am

CannabisNewsBreaks – Canopy Rivers Inc.’s (TSX: RIV) (OTC: CNPOF) PharmHouse Increases Bank Debt Facility by $10M, Signifying Confidence in the Joint Venture

Canopy Rivers (TSX: RIV) (OTC: CNPOF), a venture capital firm specializing in cannabis, today announced that its 49%-owned joint venture in Leamington, Ontario, PharmHouse Inc., amended its syndicated credit facility ("Credit Facility") with the Bank of Montreal ("BMO"), as the agent and lead lender, and the Canadian Imperial Bank of Commerce and Concentra Bank (together with BMO, the "Lenders"). According to the update, the amended terms provide PharmHouse with an additional $10 million of secured debt financing, representing an increase to the Credit Facility that was initially announced in January 2019. “This incremental debt financing, which comes at a time…

Continue Reading